Valuation Eli Lilly and Company

Equities

Real-time Estimate Cboe BZX Other stock markets 03:29:05 2024-09-18 pm EDT			5-day change	1st Jan Change
909.74 ^USD	+0.39%		-1.32%	+55.89%

09:10pm	Hims & Hers offers compounded Wegovy for $99 a month to select professions	RE
03:00pm	Axcelead Drug Discovery Partners, Inc and Eli Lilly and Company Enters into Research and Collaboration Agreement	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	126,190	153,067	250,419	347,613	524,224	815,948	-	-
Change	-	21.3%	63.6%	38.81%	50.81%	55.65%	-	-
Enterprise Value (EV) ¹	139,069	165,981	263,395	361,640	546,522	837,362	831,745	819,593
Change	-	19.35%	58.69%	37.3%	51.12%	53.22%	-0.67%	-1.46%
P/E ratio	14.8x	24.9x	45.1x	53x	101x	58.4x	42.7x	33.3x
PBR	48.3x	28.6x	29.4x	32.7x	48.9x	40.3x	23.6x	15.3x
PEG	-	-1.1x	-4.57x	4.2x	-6.3x	0x	1.2x	1.2x
Capitalization / Revenue	5.65x	6.24x	8.84x	12.2x	15.4x	17.6x	14.2x	11.9x
EV / Revenue	6.23x	6.76x	9.3x	12.7x	16x	18.1x	14.5x	12x
EV / EBITDA	18.4x	19.3x	26.3x	38.2x	63.7x	44x	32.4x	25.1x
EV / EBIT	22.9x	22.8x	31.1x	45.5x	77.4x	47.7x	35.2x	27x
EV / FCF	36.6x	32.5x	44.3x	69.1x	690x	100x	68x	45.8x
FCF Yield	2.73%	3.08%	2.26%	1.45%	0.15%	1%	1.47%	2.19%
Dividend per Share ²	2.58	2.96	3.4	3.92	4.52	5.193	5.993	6.765
Rate of return	1.96%	1.75%	1.23%	1.07%	0.78%	0.57%	0.66%	0.75%
EPS ²	8.89	6.79	6.12	6.9	5.8	15.51	21.24	27.18
Distribution rate	29%	43.6%	55.6%	56.8%	77.9%	33.5%	28.2%	24.9%
Net sales ¹	22,320	24,540	28,318	28,541	34,124	46,251	57,467	68,497
EBITDA ¹	7,551	8,589	10,005	9,472	8,584	19,019	25,670	32,688
EBIT ¹	6,079	7,265	8,457	7,950	7,057	17,544	23,621	30,336
Net income ¹	8,318	6,194	5,582	6,245	5,240	13,932	18,897	24,547
Net Debt ¹	12,879	12,914	12,976	14,027	22,298	21,415	15,797	3,645
Reference price ²	131.43	168.84	276.22	365.84	582.92	906.18	906.18	906.18
Nbr of stocks (in thousands)	960,131	906,582	906,592	950,178	899,307	900,426	-	-
Announcement Date	1/30/20	1/29/21	2/3/22	2/2/23	2/6/24	-	-	-

¹USD in Million²USD

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield (Y)	Capi. ($)
ELI LILLY AND COMPANY	58.43x	18.1x	44.03x	+0.57%	816B
NOVO NORDISK A/S	39.78x	13.85x	28.21x	+1.26%	597B
JOHNSON & JOHNSON	21.39x	4.63x	13.08x	+2.80%	402B
ABBVIE INC.	37.65x	7.14x	15.41x	+3.22%	342B
MERCK & CO., INC.	15.77x	5.01x	11.47x	+2.60%	300B
ROCHE HOLDING AG	15.97x	3.78x	9.76x	+3.70%	253B
ASTRAZENECA PLC	28.23x	5.08x	15.2x	+1.97%	244B
NOVARTIS AG	21.48x	4.95x	12.53x	+3.27%	234B
AMGEN INC.	51.27x	6.9x	12.08x	+2.76%	179B
PFIZER, INC.	21.9x	3.74x	10.22x	+5.58%	169B
Average	31.19x	7.32x	17.20x	+2.77%	353.59B
Weighted average by Cap.	35.76x	9.63x	22.55x	+2.22%